4548 On Other Exchanges
Symbol
Exchange
4548 is not on other exchanges.

seikagaku corp (4548) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEIKAGAKU CORP (4548)
\

Related News

No related news articles were found.

seikagaku corp (4548) Related Businessweek News

No Related Businessweek News Found

seikagaku corp (4548) Details

Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates through Pharmaceuticals and LAL segments. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, SUPARTZ FX, ARTZAL, etc.; ophthalmic surgical aids under the brands OPEGAN, OPEGAN Hi, and SHELLGAN; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name of Gel-One. The company also provides bulk products comprising sodium hyaluronate, which is used as a raw material for the manufacturers of pharmaceuticals; and sodium chondroitin sulfate that is used as a raw material in pharmaceuticals, ophthalmic products, and drinks for nutritional fortification. In addition, it develops endotoxin-detecting reagents for use in quality control in the manufacturing process and release test of pharmaceuticals and medical devices, as well as in quality management of fluids for hemodialysis under the Pyrochrome, ENDOSPECY, TOXICOLOR, etc. brands. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; and SI-613, a formulation for knee osteoarthritis. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.

687 Employees
Last Reported Date: 06/20/17
Founded in 1947

seikagaku corp (4548) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

seikagaku corp
Seikagaku Corp. Revised Consolidated Earnings Guidance for the Year Ending March 31, 2018

Seikagaku Corp. revised consolidated earnings guidance for the year ending March 31, 2018. For the year ending March 31, 2018, on consolidated basis, the company now expects net sales of JPY 30,100 million, operating income of JPY 1,400 million, ordinary income of JPY 5,250 million and net income attributable to owners of parent of JPY 3,800 or JPY 67.13 per share compared to net sales of JPY 30,300 million, operating income of JPY 1,500 million, ordinary income of JPY 3,750 million and net income attributable to owners of parent of JPY 2,700 or JPY 47.65 per share as previously forecasted. Net sales are projected to be slightly less than previous forecast, primarily as a result of lower sales of pharmaceutical products in Japan. Profit indicators will be mixed, however. Although a decline in revenues is causing operating income to be below forecast, ordinary income and net income attributable to owners of parent are projected to be greater than previous forecast. This is because of non-operating income generated by royalties received.

Bioventus to Continue Distributing SUPARTZ FX through 2028

Bioventus has entered into an extension of its agreement with Seikagaku Corporation to continue distributing SUPARTZ FX, a five-injection, hyaluronic acid (HA) product used for joint lubricationin the treatment of pain associated with knee osteoarthritis (OA). Under terms of this new agreement, Bioventus will be the exclusive distributor of SUPARTZ FX in the US through May 2028.

Seikagaku Corporation Announces Consolidated Earnings Results for the Nine Months Ended Dec. 31, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018

Seikagaku Corporation announced consolidated earnings results for the nine months ended Dec. 31, 2017. For the period, the group reported net sales of ¥23,401 million, operating income of ¥3,131 million, ordinary income of ¥5,889 million and net income attributable to owners of parent of ¥4,350 million or ¥76.87 per share compared to net sales of ¥22,128 million, operating income of ¥881 million, ordinary income of ¥2,016 million and net income attributable to owners of parent of ¥1,481 million or ¥26.14 per share reported in the same period last year. The increase in net sales is attributable to increases in shipments of domestic and overseas pharmaceuticals and the impact of yen depreciation. For the year ending March 31, 2018, the group expects to report consolidated net sales of ¥30,300 million, operating income of ¥1,500 million, ordinary income of ¥3,750 million and net income attributable to owners of parent of ¥2,700 million or ¥47.65 per share.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4548 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4548.
View Industry Companies
 

Industry Analysis

4548

Industry Average

Valuation 4548 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SEIKAGAKU CORP, please visit www.seikagaku.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.